DLL3 drug race expands beyond bispecific T-cell engagers

As Amgen Inc.’s Imdelltra (tarlatamab) pushes into the first-line setting for small-cell lung cancer, a fast-growing field of DLL3-directed T-cell engagers, antibody-drug conjugates and cell therapies are emerging to challenge the evolving standard of care.